L 653328Alternative Names: BPPA
Latest Information Update: 22 Jul 1998
At a glance
- Originator Merck & Co
- Class Antiglaucomas
- Mechanism of Action Beta-adrenergic receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Glaucoma
Most Recent Events
- 22 Jul 1998 No-Development-Reported for Glaucoma in USA (Ophthalmic)
- 30 Dec 1993 Phase-II clinical trials for Glaucoma in USA (Ophthalmic)